SCHEMBL3237396

SCHEMBL3237396

COc1ccc(CS(=O)(=O)Cc2ccc(OC)cc2)cc1.[Na].[Na]

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.56
KMT2A Q03164 3/20 0.55
APLNR P35414 1/20 0.53
MEN1 O00255 2/20 0.53
ALDH1A1 P00352 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
IDO1 P14902 1/20 0.50
PLCG1 P19174 1/20 0.50
CRBN Q96SW2 1/20 0.50
CA1 P00915 3/20 0.49
CA2 P00918 3/20 0.49
CA9 Q16790 3/20 0.49
CA12 O43570 2/20 0.49
CA14 Q9ULX7 2/20 0.49
BCHE P06276 1/20 0.49
ACHE P22303 1/20 0.49
HTT P42858 1/20 0.49
CA5A P35218 1/20 0.49
CA7 P43166 2/20 0.48
CA4 P22748 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30496480 1.00 PKM (0.56) PKMKMT2AAPLNRMEN1ALDH1A1
SCHEMBL2717301 0.98 KMT2A (0.57) PKMKMT2AAPLNRMEN1ALDH1A1
SCHEMBL3237393 0.96 KMT2A (0.55) PKMKMT2AAPLNRMEN1ALDH1A1
SCHEMBL13611748 0.89 KMT2A (0.54) PKMKMT2AAPLNRMEN1ALDH1A1
SCHEMBL832030 0.85 KMT2A (0.55) KMT2AMEN1HTT
SCHEMBL17230509 0.84 KMT2A (0.50) PKMKMT2AAPLNRMEN1ALDH1A1
SCHEMBL14426921 0.84 KMT2A (0.50) PKMKMT2AAPLNRMEN1SMN1; SMN2
SCHEMBL294919 0.83 APLNR (0.53) PKMKMT2AAPLNRALDH1A1SMN1; SMN2
SCHEMBL2377998 0.83 APLNR (0.58) PKMKMT2AAPLNRALDH1A1SMN1; SMN2
SCHEMBL24188499 0.81 ALDH1A1 (0.55) PKMKMT2AAPLNRMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735620-B2 Processes for preparing (E)-styrylbenzylsulfone compounds and uses thereof for treating proliferative disorders EPR PHARMACEUTICALS PVT. LTD (IN) 2014-05-27 US disclosed
US-20100152491-A1 PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS EPR PHARMACEUTICALS PVT.LTD 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152491-A1 PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS PCNA, CDC25B, CCNB1 PKM 1008/4885KMT2A 3132/4885APLNR 3668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.